Samsung Biologics has announced the launch of its proprietary cell line technology, S-CHOice.   According to the company, S-CHOice builds on glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line technology and shows improved titers up to two-fold from industry average, reaching above 7 g/L for standard monoclonal antibodies. The cell line also shows enhanced cell viability with over 90% at day-21 in a fed-batch study, demonstrating effectiveness in producing high quality cell l...